Skip to main content

Genome Technology s Lab Notebook: Reader Tips and Experiences: Mar 17, 2005

Following is a scientist's responses to the question, "If an RNAi experiment results in insufficient gene knockdown, do you try the experiment again? If so, what approach do you use to improve the knockdown?"

 

For a complete list of scientists' responses, read the March issue of Genome Technology, a GenomeWeb News sister publication.


"In general we go through a triage process. Our first approach is to try the knockdown in another cell line that we know has high levels of RNAi activity. Second we tend to order a few more RNAi's around the target (provided we have not tried five or more in the first go around). If we have not seen transcript knockdown at this point, we may begin to suspect that the primer sets that we are using are incorrect, and so we will take another look at the same samples with new primers.

 

"When looking at protein levels we may suspect that antibodies are not very specific or that the protein has an unusually long half life. We may then use an epitope tagged cDNA overexpression approach to look for activity. When using this approach we prefer to overexpress the protein, wait 24 hours and then attempt the RNAi knockdown."

 

Kevin FitzGerald

Group leader for emerging technologies

Applied Genomics Bristol-Myers Squibb

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.